Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

about

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

Item

http://www.wikidata.org/entity/Q54119186

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@en

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@nl

type

Item

label

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@en

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@nl

prefLabel

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@en

Excellent outcomes of 2G-TKI t ...... in chronic phase CML patients.

@nl

P1476

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients

@en

P2093

Achille Ambrosetti

http://www.w3.org/2001/XMLSchema#string

Alessandra Iurlo

http://www.w3.org/2001/XMLSchema#string

Anna Guella

http://www.w3.org/2001/XMLSchema#string

Claudia Minotto

http://www.w3.org/2001/XMLSchema#string

Cristina Bucelli

http://www.w3.org/2001/XMLSchema#string

Elena Maino

http://www.w3.org/2001/XMLSchema#string

Elisabetta Calistri

http://www.w3.org/2001/XMLSchema#string

Ercole De Biasi

http://www.w3.org/2001/XMLSchema#string

Federico De Marchi

http://www.w3.org/2001/XMLSchema#string

Filippo Gherlinzoni

http://www.w3.org/2001/XMLSchema#string

P2860

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

P304

14219-14227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24478

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario Tiribelli

Nicola Orofino

P577

2018-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29581839

http://www.w3.org/2001/XMLSchema#string

P932

5865665

http://www.w3.org/2001/XMLSchema#string